delgocitinib
Ligand Summary
Delgocitinib, a janus kinase (JAK) inhibitor, is being approved for the treatment of inflammatory skin conditions. Delgocitinib inhibited the activation of inflammatory cells, such as T cells, B cells, monocytes and mast cells, in vitro and inhibited Th1-, Th2- and Th17-type cytokine production from both T cells and non-T cells.
UNII: 9L0Q8KK220
PubChem: 50914062
Guide to Pharmacology: 9619
ChEMBL: CHEMBL4297507
DrugCentral: 5426
LyCHI: ZWTZNF94YLU7
Target Activities
11 Activities
Items per page:
1 – 10 of 11
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
Ki | ||||||
Ki | ||||||
IC50 | ||||||
Ki | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | INHIBITOR | |||||
IC50 | INHIBITOR | |||||
IC50 | INHIBITOR | |||||